Spinal accessory nerve stimulation during neck dissection (SANE)
| ISRCTN | ISRCTN13360401 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13360401 |
| Integrated Research Application System (IRAS) | 359693 |
| Central Portfolio Management System (CPMS) | 75510 |
| Sponsor | University of Oxford |
| Funder | Oracle Head and Neck Cancer UK Limited |
- Submission date
- 07/08/2026
- Registration date
- 07/10/2026
- Last edited
- 07/10/2026
- Recruitment status
- Not yet recruiting
- Overall study status
- Ongoing
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
People with head and neck cancer sometimes need an operation called a neck dissection to remove lymph nodes from the neck. During this operation, a nerve called the spinal accessory nerve can be stretched or injured. This nerve helps control shoulder movement, and injury can lead to shoulder pain, weakness and difficulty moving the arm. These problems can persist for many months after surgery and can affect everyday activities and ability to work.
Research suggests that applying a small electrical current to an injured nerve during surgery may help the nerve recover. Previous studies have used 60 minutes of electrical stimulation, but this may be difficult to introduce routinely because of the additional operating time. Research suggests that a shorter period of 10 minutes may also be beneficial.
The SANE study is a small pilot study. Its main aim is not to determine whether the treatment works, but to find out whether a larger study comparing 10 minutes of nerve stimulation with standard care can be successfully carried out in the NHS. We will assess whether patients can be recruited and followed up, whether the treatment can be delivered as planned, and whether it is acceptable to the surgical team.
Who can participate?
We aim to recruit 14 adults aged over 18 years with head and neck cancer who are due to have a neck dissection as part of treatment intended to cure their cancer. Participants must be able and willing to provide informed consent.
People will not be able to take part if they have previously had a neck dissection, have existing neurological or shoulder problems, have an implanted electrical device such as a pacemaker, or if the spinal accessory nerve or trapezius muscle needs to be removed during surgery.
What does the study involve?
Participants will be randomly allocated to one of two groups. One group will receive their usual NHS care. The other group will receive usual NHS care plus 10 minutes of electrical stimulation of the spinal accessory nerve during their neck dissection. The stimulation is given while the participant is under general anaesthetic. Participants will not know which group they have been allocated to.
Before surgery, participants will complete questionnaires about their shoulder function and quality of life and undergo tests of shoulder movement and nerve function. Blood samples will also be collected to investigate biological factors that may be related to nerve injury and recovery.
Participants will be followed up at 3, 6 and 12 months after surgery. The shoulder and nerve assessments and questionnaires will be repeated at these visits. Wherever possible, study visits will take place alongside routine hospital appointments to reduce inconvenience.
Each participant is expected to be involved in the study for approximately 15 months, from initial telephone screening until the final 12-month follow-up.
What are the possible benefits and risks of participating?
As this is a pilot study, it is not designed to show whether nerve stimulation improves shoulder function. Participants who receive nerve stimulation may experience improved nerve recovery and shoulder function, but this cannot be guaranteed. All participants may benefit from the additional monitoring and assessments provided during the study. The information collected will help researchers design a larger trial and may help improve care for future patients undergoing neck dissection.
Nerve stimulation is considered low risk, and previous studies have not reported treatment-related nerve injury or damage to surrounding tissues. For participants receiving stimulation, the procedure may slightly increase the length of the operation and time under general anaesthetic. Blood tests may cause temporary discomfort, bruising or light-headedness. Tests of nerve and shoulder function may cause mild discomfort or tiredness, and some questions about health and wellbeing may be upsetting. Participants can take breaks or decline to answer questions if they wish.
Where is the study run from?
The study is being conducted at Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. It is a single-centre study.
When is the study starting and how long is it expected to run for?
The study is expected to start on 1 October 2026. Participant recruitment is planned from 1 January 2027 to 1 July 2027.
Participants will be followed for 12 months after surgery. The overall study is expected to run until 1 March 2030, allowing time for completion of follow-up, data collection, data checking and analysis. The study will be considered complete when the final participant's follow-up data have been entered and all outstanding data queries have been resolved.
Who is funding the study?
The study is funded by ORACLE Head & Neck Cancer UK.
Who is the main contact?
Mr Akira Wiberg, akira.wiberg@ndorms.ox.ac.uk
Contact information
Principal investigator, Scientific, Public
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
Oxford
OX3 7LD
United Kingdom
| Phone | +44 1865 227 374 |
|---|---|
| akira.wiberg@ndorms.ox.ac.uk |
Public, Scientific, Principal investigator
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
Oxford
OX3 7LD
United Kingdom
| Phone | +44 1865 227 374 |
|---|---|
| dominic.furniss@ndorms.ox.ac.uk |
Public, Scientific, Principal investigator
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
Oxford
OX3 7LD
United Kingdom
| Phone | +44 1865 223556 |
|---|---|
| stuart.winter@nds.ox.ac.uk |
Public, Principal investigator, Scientific
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
Oxford
OX3 7LD
United Kingdom
| Phone | +44 1865 223556 |
|---|---|
| yuri.bow-liu@msd.ox.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Active |
| Assignment | Single |
| Purpose | Treatment |
| Participant information sheet | 50054 SANE Participant Patient Information Sheet v1.0 22Mar2026.pdf |
| Scientific title | Spinal accessory nerve stimulation during neck dissection (SANE): a randomised, single-blind, single-centre external pilot study |
| Study acronym | SANE |
| Study objectives | To assess the feasibility, fidelity and acceptability of delivering 10 minutes of intra-operative spinal accessory nerve stimulation during neck dissection within an NHS setting, to inform the design of a definitive randomised controlled trial. |
| Ethics approval(s) |
Approved 23/03/2026, University of Oxford Research Governance, Ethics & Assurance, Joint Research Office (University of Oxford, Boundary Brook House, Churchill Drive, Headington, Oxford, OX3 7GB, United Kingdom; no telephone number provided; rgea.sponsor@admin.ox.ac.uk), ref: 26/SC/0259 |
| Health condition(s) or problem(s) studied | Head and Neck Cancer |
| Intervention | Study design: This is a single-centre, parallel-group, two-arm, single-blind, randomised controlled external pilot study. The trial will evaluate the feasibility of delivering intra-operative spinal accessory nerve stimulation for 10 minutes, compared with standard care alone, in patients undergoing neck dissection. The study will be conducted at a tertiary NHS surgical centre in England. Blinding: Participants will be blinded to their treatment allocation. Owing to the intra-operative nature of the intervention, outcome assessors, research staff, and members of the surgical team will not be blinded. Eligibility and recruitment: All adults aged ≥18 years scheduled for curative-intent neck dissection will be screened for eligibility. Screening logs will document the numbers of patients assessed, eligible, excluded, and enrolled. Eligible patients attending head and neck cancer clinics at Churchill Hospital, across Plastic Surgery, ENT, and Oral & Maxillofacial Surgery, will be identified by the clinical team and approached by a research team member to provide informed consent. Randomisation: Participants will be randomised via a secure web-based system to one of two groups (control or 10-minute stimulation). Allocation will be stratified by age, sex, extent of neck dissection, and receipt of pre-operative chemotherapy. Baseline assessments: Following randomisation, baseline measures will include: 1. Demographics 2. Neck Dissection Impairment Index (NDII) 3. Shoulder Pain and Disability Index (SPADI) 4. Goniometry (shoulder range of motion) 5. Neurophysiological assessment of the spinal accessory nerve 6. Health-related quality of life: EORTC QLQ-C30, QLQ-H&N35, and EQ-5D-5L 7. Blood sample for genotyping of Val66Met (rs6265) BDNF polymorphism and NfL measurement Intervention: Treatment allocation will be disclosed to the surgical team on the day of surgery. In the intervention group, electrical stimulation will be delivered intra-operatively by a trained surgeon in collaboration with a research team member, in accordance with a standard operating procedure. In the intervention group, electrodes will be applied directly to the spinal accessory nerve for 10 minutes of stimulation. Participants randomised to the control group will receive standard care, and their surgical procedure will be conducted as per routine practice. Electrodes will not be applied to the spinal accessory nerve. Operative duration (knife-to-skin to closure) will be recorded, and intervention fidelity will be documented using a standardised checklist. All participants will receive standard post-operative care, including physiotherapy and routine surgical follow-up. Follow-up assessments: Participants will be followed at 3, 6, and 12 months post-operatively, coordinated with routine clinical appointments. At each time point, outcome measures collected at baseline (excluding the blood sample) will be repeated, together with a global patient-reported rating of change in shoulder function. Data will be entered directly into a secure REDCap database. Upon completion of the feasibility study, all participants will be invited to complete a brief questionnaire regarding their experience of taking part in the study. Feasibility outcomes: Feasibility will be assessed using: 1. Recruitment and retention rates 2. Compliance with intervention delivery and follow-up assessments 3. Completeness of data collection 4. Screening logs to capture eligibility and reasons for non-participation Qualitative sub-study: A nested qualitative sub-study will explore the acceptability of the intervention to the surgical team. Six members of the operative and anaesthetic teams, two surgeons, two anaesthetists, and two scrub nurses or equivalent staff, will each participate in a one-hour semi-structured interview to provide qualitative insights into the feasibility of the 10-minute stimulation protocol. A deductive theory driven approach using the Sekhon’s TFA will be used to structure analysis. |
| Intervention type | Other |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
1. Proportion of randomised participants receiving their allocated treatment measured using the study eCRF and intervention record on the day of surgery |
| Completion date | 01/03/2030 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 120 Years |
| Sex | All |
| Target sample size at registration | 14 |
| Key inclusion criteria | Patients in primary study: 1. Competent adult patients with head and neck cancer who are scheduled to undergo neck dissection including level 2b +/- level 5 2. Willing and able to give informed consent for participation in the trial. 3. Age >18 years, male or female 4. Surgery is intended to be curative Healthcare professionals in qualitative sub-study: 1. Surgical consultant, surgical registrar, anaesthetic consultant, anaesthetic registrar, scrub nurse or operating department practitioner involved in the 10-min stimulation arms 2. Willing and able to give consent |
| Key exclusion criteria | Patients in primary study: 1. Previous neck dissection 2. Intra-operative resection of spinal accessory nerve or trapezius 3. Pre-existing neurological or shoulder dysfunction 4. Implanted electrical device e.g. pacemaker Healthcare professionals in qualitative sub-study: 1. Lack of English language proficiency |
| Date of first enrolment | 01/01/2027 |
| Date of final enrolment | 01/07/2027 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Oxford
OX3 7LE
England
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan | he datasets generated during and/or analysed during the current study are/will be available upon request from Mr Akira Wiberg, akira.wiberg@ndorms.ox.ac.uk |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | version 1.0 | 22/03/2026 | 06/10/2026 | No | Yes |
Additional files
- 50054 SANE Participant Patient Information Sheet v1.0 22Mar2026.pdf
- Participant information sheet
Editorial Notes
07/08/2026: Trial's existence confirmed by the National Institute for Health and Care Research (NIHR) (UK).